Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials

Jonathan Cheng, Justin Wayne Wong Tiu-lim, Sheng Zhou, Anthony B. El-Khoueiry, Jorge J. NievaFrontiers in Oncology 2019 · DOI

TL;DR

This study reveals that mandatory fresh tissue biopsies for biomarker testing in clinical trials significantly delay treatment initiation. While these delays didn't impact overall trial duration or progression-free survival in this cohort, they were often not clearly communicated in informed consent forms, potentially impacting patient expectations.

What Problem Does This Paper Address?

The increasing use of targeted therapies and immunotherapies in oncology relies heavily on identifying specific biomarkers within tumor tissue. This has led to a growing requirement for fresh tumor biopsies for biomarker analysis as a prerequisite for enrolling patients in clinical trials. While previous studies hinted at this, the authors aimed to confirm whether these mandatory biopsies indeed lead to delays in starting treatment and to quantify this impact. This is crucial because cancer patients often have limited time and are seeking the most effective treatments promptly. Understanding these delays is vital for optimizing clinical trial design and patient care.

Methods

The researchers conducted a retrospective analysis of 76 patients enrolled in clinical trials at the USC Norris Comprehensive Cancer Center between January 2013 and May 2018. They divided patients into two groups: those who required a fresh research biopsy before treatment (research biopsy group) and those who did not, using archival tissue instead (no biopsy group). They meticulously collected data from electronic medical records, focusing on the time from biopsy consent or initial clinical trial consent to treatment initiation, time on trial until disease progression, and total time on trial. Statistical analysis, including unpaired t-tests, was used to compare outcomes between the two groups.

Datasets

The study utilized retrospective data from the electronic medical records of 76 patients treated at the USC Norris Comprehensive Cancer Center. No new datasets or benchmarks were introduced.

Key Insights and Ideas

  • The "Biopsy Bottleneck": The core finding is that the logistical requirements of obtaining and processing fresh tissue for biomarker analysis create a significant bottleneck, delaying the start of potentially life-saving treatments.
  • Informed Consent Gap: A concerning observation is that the informed consent documents for trials requiring these biopsies often failed to adequately communicate the potential for treatment delays, leaving patients and clinicians potentially unaware of this consequence.
  • No Immediate Survival Impact (in this cohort): While delays were observed, this particular study did not find a statistically significant difference in the time patients spent on trial or the time until disease progression between the biopsy and no-biopsy groups. This suggests that while initiation is delayed, the treatment itself might still be effective for a similar duration once started.
  • The Rise of Liquid Biopsies: The authors highlight liquid biopsies (e.g., cfDNA, ctDNA from blood or saliva) as a promising alternative that could potentially circumvent the delays and complications associated with tissue biopsies, allowing for faster enrollment and more frequent monitoring.

Key Results

  • Trials requiring a fresh research biopsy had a significantly longer median screening duration: 30 days compared to 14 days for trials that did not require a biopsy (p < 0.0001).
  • The research biopsy group experienced a median of 30 days from biopsy consent or initial clinical trial consent to treatment initiation, while the no-biopsy group had a median of 14 days.
  • While 9.1% of patients in the research biopsy group experienced biopsy complications, no patients dropped out of the study due to these complications.
  • No statistically significant differences were found in the median time on trial before disease progression (112 vs. 119 days) or the total time on clinical trial (112 vs. 105 days) between the groups.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single Institution Study: The findings are based on data from one cancer center, which may limit generalizability.
  • Heterogeneity: The study included a mix of malignancies and clinical trial treatments, which could introduce variability.
  • Retrospective and Non-Randomized: The retrospective nature means causality cannot be definitively proven, and the lack of randomization might introduce biases.

Future work should focus on:

  • Prospective Studies: Designing prospective studies to better understand the impact of these delays on patient outcomes and survival.
  • Informed Consent Improvement: Revising informed consent forms to clearly articulate the potential for treatment delays associated with mandatory research biopsies.
  • Liquid Biopsy Research: Further investigation into the accuracy and utility of liquid biopsies for biomarker testing in clinical trials to streamline the process.
  • Biomarker Dynamic Assessment: Developing better methods to assess whether fresh biopsies are truly necessary by comparing them with archival tissue and understanding biomarker dynamics.

Summary updated

Abstract

<b>Background:</b> There has been an increasing requirement for fresh tumor tissue to enroll in clinical trials in order to look for specific biomarkers. This has been shown to increase screening duration and increase screen failure rates. It was important to corroborate these results in other centers. <b>Methods:</b> This study is a non-randomized retrospective analysis of patients in one subset of patients seen by research nurses who operated in the standard head/neck and lung team not including patients in the phase 1 program. All patients were enrolled in clinical trials from January 16, 2013 to May 28, 2018 at USC Norris Comprehensive Cancer Institute in Los Angeles. Patients who were required to give fresh research biopsies prior to intervention were part of the research biopsy group. <b>Results:</b> In total, 76 patients were analyzed in this study. Thirty-three patients were in the research biopsygroup and 43 patients were in the no biopsy group. Trials that required a fresh biopsy had a longer median screening duration (30 vs. 14 days) than trials that did not require a biopsy (<i>p</i> < 0.0001). <b>Conclusions:</b> Our study shows that requiring biopsies prior to clinical trial treatment results in a statistically significant delay in treatment. The informed consent forms that were part of clinical trials involving mandatory research biopsies did not reflect this delay in treatment. However, these delays did not result in a statistically significant decrease in number of days on trial or days until progression of disease.
BibTeX
@inproceedings{cheng2019mandatory,
  author = {Jonathan Cheng and Justin Wayne Wong Tiu-lim and Sheng Zhou and Anthony B. El-Khoueiry and Jorge J. Nieva},
  title = {{Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials}},
  booktitle = {Frontiers in Oncology},
  year = {2019},
  doi = {10.3389/fonc.2019.00968},
}
Figure